#China #Xi'an #Immunoassay #KHB #Polaris V150

KHB Unveils the Polaris V150 Chemiluminescent Immunoassay Analyzer at MEDICA 2025

In a remarkable showcase of innovation, Shanghai Kehua Bio-engineering Co., Ltd. (KHB), a renowned global provider of in vitro diagnostic solutions, has introduced its latest chemiluminescent immunoassay analyzer, the Polaris V150, at MEDICA 2025. This event is considered one of the most significant medical trade fairs worldwide, and KHB's recent offering is a testament to its continued commitment to advancing automated diagnostics.

Designed for Versatility and Efficiency

The Polaris V150 is specifically engineered for use in small to medium-sized laboratories as well as for urgent and emergency testing in larger hospitals and external laboratories. Despite its compact size of only 0.36 square meters, this powerful desktop analyzer boasts an impressive testing capability of 150 assays per hour. This efficiency is crucial for laboratories operating in space-constricted environments, allowing for continuous loading of samples, reagents, and reaction vessels while catering to urgent sample testing through its STAT function.

The analyzer is equipped with 40 sample positions and is compatible with both serum and plasma testing. Furthermore, Polaris V150 includes automated dilution capabilities along with comprehensive detection for liquid levels, clots, and collisions, enhancing workflow reliability and reducing human error in lab results.

Advanced Technology for Accurate Results

Featuring high-performance ALP-AMPPD technology, the Polaris V150 guarantees exceptional accuracy and precision with a coefficient of variation (CV) below 3% across all tests. The integrated all-in-one reagent kit contains QR-coded calibrators and a master curve that standardizes operation while simplifying reagent management. This ensures users can trust the reliability of the results produced by this analyzer.

Expansive Test Menu and Smart Systems

The analyzer supports an internally developed test menu that encompasses more than 60 assays across 10 major disease panels. This range of tests includes essential markers for thyroid function, sex hormones, tumor markers, infectious diseases, cardiac markers, inflammation, blood glucose, anemia, and bone metabolism among others, catering to diverse diagnostic needs.

KHB has invested in creating an intelligent system design for enhanced user experience. The Polaris V150 enables real-time monitoring of reagent and consumable statuses, ensuring laboratories maintain optimal operational visibility. The clean and intuitive user interface, combined with a built-in touchscreen, facilitates efficient navigation and operation, effectively minimizing training needs and improving overall user satisfaction.

Reliable Reagent Stability and Smart Maintenance

To uphold continuous high-quality performance, the analyzer incorporates integrated refrigeration, maintaining temperatures between 2 to 8 degrees Celsius for up to 12 reagent positions, ensuring optimal reagent stability. Additionally, features such as remote monitoring and automated maintenance streamline service workflows and reduce downtime, thus ensuring laboratories can achieve greater operational continuity.

A Highlight at MEDICA 2025

At MEDICA 2025, the Polaris V150 emerged as a flagship product at KHB's booth, attracting attention from international partners interested in compact and efficient immunoassay solutions. Live demonstrations, alongside technical consultations conducted by the KHB expert team, provided visitors with profound insights into the instrument's capabilities and its suitability for both routine and emergency lab environments.

The overwhelming interest garnered at MEDICA showcases the growing demand for high-quality, compact chemiluminescent systems like the Polaris V150. As stated by KHB’s product manager, "We are excited to share this innovation with our international partners and support laboratories worldwide with efficient immunoassay solutions."

About KHB Group

Shanghai Kehua Bio-engineering Co., Ltd. (KHB, Stock Code: 002022.SZ) is deeply rooted in the field of in vitro diagnostics, offering a comprehensive range of medical diagnostic products specializing in immunological, biochemical, molecular diagnostics, and point-of-care testing (POCT). Since its inception in 1981, KHB has established itself as a high-tech company integrating R&D, manufacturing, and marketing operations. The company was listed on the Shenzhen Stock Exchange (SZSE) in 2004.

For more information, visit KHB's official website and their LinkedIn, Facebook, and Twitter pages for updates and news.